Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer.
Shiozawa T, Numata T, Tamura T, Endo T, Kaburagi T, Yamamoto Y, Yamada H, Kikuchi N, Saito K, Inagaki M, Kurishima K, Funayama Y, Miyazaki K, Koyama N, Furukawa K, Nakamura H, Kikuchi S, Ichimura H, Sato Y, Sekine I, Satoh H, Hizawa N.
Shiozawa T, et al. Among authors: funayama y.
Anticancer Res. 2022 May;42(5):2583-2590. doi: 10.21873/anticanres.15736.
Anticancer Res. 2022.
PMID: 35489768